A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal antibody, has shown activity and an acceptable safety profile...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hematol Oncol
Autori principali: Sehn, Laurie H., Martelli, Maurizio, Trněný, Marek, Liu, Wenxin, Bolen, Christopher R., Knapp, Andrea, Sahin, Deniz, Sellam, Gila, Vitolo, Umberto
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Rapid Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7276080/
https://ncbi.nlm.nih.gov/pubmed/32505213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00900-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi